Your browser is no longer supported. Please, upgrade your browser.
NGM Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own1.20% Shs Outstand77.10M Perf Week-2.29%
Market Cap1.49B Forward P/E- EPS next Y-2.23 Insider Trans-12.05% Shs Float54.50M Perf Month-14.91%
Income-122.00M PEG- EPS next Q-0.35 Inst Own67.70% Short Float1.45% Perf Quarter-10.01%
Sales81.60M P/S18.24 EPS this Y-75.90% Inst Trans1.33% Short Ratio2.11 Perf Half Y-31.03%
Book/sh4.84 P/B3.97 EPS next Y-26.80% ROA-32.00% Target Price34.83 Perf Year13.12%
Cash/sh5.04 P/C3.81 EPS next 5Y- ROE-36.70% 52W Range14.90 - 32.12 Perf YTD-36.52%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.22% Beta-
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin- 52W Low28.86% ATR0.95
Employees210 Current Ratio8.90 Sales Q/Q-15.20% Oper. Margin- RSI (14)37.87 Volatility3.21% 4.78%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.90% Profit Margin- Rel Volume0.32 Prev Close19.23
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume373.64K Price19.20
Recom2.00 SMA20-5.89% SMA50-11.04% SMA200-20.03% Volume58,009 Change-0.16%
Sep-13-21Upgrade Raymond James Outperform → Strong Buy $27 → $39
May-24-21Downgrade Raymond James Strong Buy → Outperform $52 → $22
Jul-31-20Initiated Piper Sandler Overweight $30
Jul-07-20Initiated Chardan Capital Markets Buy $40
Jun-05-20Initiated BMO Capital Markets Outperform $30
Apr-07-20Initiated Raymond James Strong Buy $31
Oct-17-19Initiated B. Riley FBR Buy $24
Jun-25-19Initiated Stifel Buy
Apr-29-19Initiated Goldman Buy $22
Apr-29-19Initiated Cowen Outperform $25
Apr-29-19Initiated Citigroup Buy $29
Oct-06-21 06:40AM  
Sep-30-21 11:00AM  
Sep-16-21 03:27PM  
Sep-15-21 10:49AM  
Aug-23-21 09:00AM  
Aug-05-21 07:05PM  
Aug-04-21 03:00PM  
Jul-26-21 07:40PM  
Jul-23-21 12:00PM  
Jul-22-21 04:05PM  
Jul-07-21 07:00AM  
Jul-01-21 01:50PM  
Jun-07-21 08:00AM  
Jun-03-21 07:52AM  
Jun-02-21 10:15AM  
Jun-01-21 10:13AM  
May-31-21 10:19AM  
May-28-21 10:01AM  
May-27-21 11:00AM  
May-26-21 11:35AM  
May-25-21 11:00AM  
May-24-21 06:19PM  
May-23-21 06:00PM  
May-14-21 04:42AM  
May-06-21 07:55PM  
May-05-21 03:00PM  
Apr-28-21 04:15PM  
Mar-26-21 10:52AM  
Mar-15-21 05:06AM  
Mar-04-21 07:25PM  
Mar-02-21 08:00AM  
Feb-25-21 08:00AM  
Feb-09-21 08:00AM  
Jan-20-21 08:19AM  
Jan-14-21 03:13AM  
Jan-12-21 04:05PM  
Jan-05-21 09:55PM  
Jan-04-21 04:01PM  
Dec-11-20 10:37PM  
Dec-09-20 04:05PM  
Nov-16-20 12:05PM  
Nov-15-20 09:49AM  
Nov-13-20 08:00AM  
Nov-12-20 04:05PM  
Nov-11-20 08:00AM  
Nov-09-20 11:49AM  
Nov-05-20 08:00AM  
Nov-04-20 08:00AM  
Nov-03-20 12:30PM  
Oct-19-20 07:00AM  
Aug-29-20 07:20AM  
Aug-18-20 08:00AM  
Aug-12-20 05:45PM  
Aug-11-20 10:30AM  
Aug-07-20 08:30AM  
Aug-03-20 12:31PM  
Jul-31-20 08:00AM  
Jul-27-20 08:00AM  
Jul-05-20 05:56PM  
Jun-18-20 08:50AM  
Jun-08-20 08:00AM  
May-29-20 04:05PM  
May-27-20 04:05PM  
May-13-20 05:35PM  
May-08-20 04:05PM  
May-06-20 09:55AM  
Apr-07-20 10:59AM  
Apr-03-20 01:10PM  
Mar-17-20 04:05PM  
Mar-16-20 10:01AM  
Mar-09-20 04:30PM  
Feb-27-20 08:42AM  
Feb-26-20 04:42PM  
Feb-25-20 08:00AM  
Feb-24-20 05:47PM  
Feb-23-20 04:00PM  
Feb-11-20 08:00AM  
Feb-05-20 04:11PM  
Dec-17-19 05:43PM  
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHEN JIN-LONGChief Scientific OfficerOct 12Sale20.1415,000302,100899,449Oct 13 04:34 PM
CHEN JIN-LONGChief Scientific OfficerOct 11Sale20.4115,000306,150914,449Oct 13 04:34 PM
Lieu Hsiao DSVP, Chief Medical OfficerOct 05Option Exercise12.062,00024,1202,000Oct 07 08:04 PM
Lieu Hsiao DSVP, Chief Medical OfficerOct 05Sale22.002,00044,0000Oct 07 08:04 PM
CHEN JIN-LONGChief Scientific OfficerSep 14Sale25.6615,000384,892929,449Sep 14 09:27 PM
CHEN JIN-LONGChief Scientific OfficerSep 13Sale26.0315,000390,414944,449Sep 14 09:27 PM
Lieu Hsiao DSVP, Chief Medical OfficerAug 12Option Exercise12.068,00096,4808,000Aug 13 04:27 PM
Lieu Hsiao DSVP, Chief Medical OfficerAug 12Sale23.508,000188,0000Aug 13 04:27 PM
Lieu Hsiao DSVP, Chief Medical OfficerAug 11Sale23.002,25851,9340Aug 13 04:27 PM
CHEN JIN-LONGChief Scientific OfficerAug 10Sale23.1515,000347,250959,449Aug 11 06:48 PM
CHEN JIN-LONGChief Scientific OfficerAug 09Sale24.4615,000366,972974,449Aug 11 06:48 PM
CHEN JIN-LONGChief Scientific OfficerJun 03Option Exercise1.4469,44499,999989,449Jun 07 04:49 PM
CHEN JIN-LONGChief Scientific OfficerMay 03Sale27.6225,000690,500920,005May 04 04:39 PM
CHEN JIN-LONGChief Scientific OfficerApr 12Sale24.6525,000616,250945,005Apr 13 06:56 PM
CHEN JIN-LONGChief Scientific OfficerMar 01Sale26.6625,000666,500970,005Mar 02 05:19 PM
CHEN JIN-LONGChief Scientific OfficerFeb 16Sale28.7525,000718,750995,005Feb 17 04:19 PM
CHEN JIN-LONGChief Scientific OfficerJan 05Option Exercise0.60150,00090,0001,020,005Jan 06 07:30 PM
CHEN JIN-LONGChief Scientific OfficerJan 04Sale29.2825,000732,116870,005Jan 06 07:30 PM
CHEN JIN-LONGChief Scientific OfficerDec 14Sale28.0125,000700,276895,005Dec 16 04:34 PM
CHEN JIN-LONGChief Scientific OfficerNov 02Sale17.7025,000442,500920,005Nov 04 05:10 PM